Clinical Index of Stable Febrile Neutropenia (CISNE)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- —0–0
- —1–2
- —3–8
The Clinical Index of Stable Febrile Neutropenia (CISNE) calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include ecog performance status. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Identifies febrile neutropenia patients at low risk for serious complications. Used for adult outpatients with solid tumor, fever ≥38°C (100.4°F), and neutropenia (≤500 cells/mm³ or ≤1,000 cells/mm³ with expected decrease to 500).
Clinical Indication
The Clinical Index of Stable Febrile Neutropenia (CISNE) is indicated for bedside clinical practice to support Identifies febrile neutropenia patients at low risk for serious complications. Used for adult outpatients with solid tumor, fever ≥38°C (100.4°F), and neutropenia (≤500 cells/mm³ or ≤1,000 cells/mm³ with expected decrease to 500).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
CISNE Score = ECOG Performance Status points + Stress-induced hyperglycemia points + COPD points + Cardiovascular disease points + NCI mucositis points + Monocyte points
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| ecog_performance_status | string | Yes | ECOG Performance Status |
| stress_induced_hyperglycemia | string | Yes | Stress-induced hyperglycemia (glucose >250 mg/dL or >13.9 mmol/L, or glucose >121 mg/dL or >6.7 mmol/L with diabetes) |
| copd | string | Yes | Chronic obstructive pulmonary disease |
| cardiovascular_disease | string | Yes | Cardiovascular disease history (heart failure, ischemic heart disease, arrhythmia) |
| nci_mucositis_grade | string | Yes | NCI mucositis grade ≥2 |
| monocytes | string | Yes | Monocyte count |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | — | Low risk |
| 1–2 | — | Intermediate risk |
| 3–8 | — | High risk |
Evidence-Based References (EBM)
- Carmona-Bayonas A, Gómez J, González-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011 Aug 23;105(5):612-7. doi: 10.1038/bjc.2011.284.DOI: 10.1038/bjc.2011.284
- Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015 Feb 10;33(5):465-71. doi: 10.1200/JCO.2014.57.2347.DOI: 10.1200/JCO.2014.57.2347